Aurolife Pharma LLC – FDA 483, Apr 10, 2025
Aurolife Pharma LLC, a drug product manufacturer in Durham, NC, was cited for significant deficiencies across its quality system, laboratory controls, facilities, and equipment. The inspection revealed issues with stability testing, OOS investigations, change control, environmental monitoring, equipment cleaning, pest control, calibration, and the effectiveness of corrective and preventive actions, indicating a broad lack of adherence to GMP regulations. The firm also failed to submit a Field Alert Report in a timely manner for a distributed product with device malfunctions.
ID · dab66993-8516-44fc-bf38-26f7a17f3003
Comes with the profile
KRA (KeyPedia Risk Analysis)
How likely the FDA is to take enforcement action in the next 12 months.
Example18-month trend
Form 483 · April 10, 2025
What you get
A document
One file.
- One FDA document, such as a Form 483
- Yours for life in your Library
- Each has its own price
The profile
All the documents, plus intelligence about the company.
- Every Aurolife Pharma LLC document on file
- The KRA score, which a single document does not include
- Observations and inspection history
Access
This, for every company on KeyPedia.
- Combine profiles in one search
- Search across any modality: products, industry types, drugs, devices and recalls
- Track everything as it changes
- Other agencies too, such as EMA, Health Canada and UK MHRA